Related Experiment Videos
Plasma beta-phenylethylamine in Parkinson's disease.
1Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
The Kurume Medical Journal
|February 24, 2001
Summary
Parkinson's disease patients have significantly lower plasma beta-phenylethylamine (PEA) levels. Declining PEA levels may indicate disease progression and nigrostriatal degeneration.
Area of Science:
- Neuroscience
- Biochemistry
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder.
- Beta-phenylethylamine (PEA) is a trace amine with potential neuromodulatory roles.
Purpose of the Study:
- To investigate the relationship between plasma PEA levels and the severity/clinical course of PD.
- To determine if PEA levels can serve as a biomarker for nigrostriatal degeneration.
Main Methods:
- Plasma PEA concentrations were measured in 27 PD patients and compared to a control group.
- PEA levels were analyzed in relation to Hoehn and Yahr staging.
- Serial PEA measurements were performed in a subset of PD patients to track changes over time.
Main Results:
- PD patients exhibited significantly lower plasma PEA levels compared to controls (p < 0.0001).
- Plasma PEA concentrations did not correlate with Hoehn and Yahr disease severity.
- Progressive PD cases showed a downward trend in PEA levels over one to two years, while non-progressive cases maintained stable levels.
Conclusions:
- Plasma PEA levels are significantly reduced in Parkinson's disease.
- Plasma PEA may serve as a potential indicator of ongoing nigrostriatal degeneration in PD.
- Longitudinal PEA levels might reflect the clinical course of Parkinson's disease.